Literature DB >> 7873820

Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy.

F Ameglio1, C Bonifati, M Pietravalle, M Fazio.   

Abstract

BACKGROUND: Involvement of various cytokines in psoriasis pathomechanisms has previously been reported.
OBJECTIVE: To better define the relationship between the disease severity and interleukin-6 and tumour necrosis factor alpha skin levels, these two cytokines were measured in suction blister fluids obtained from involved and uninvolved skin areas of psoriatic patients treated with UVB, beta-methasone dipropionate and salicylic acid ointment.
METHODS: Determinations were performed by ELISA in fluids obtained from 6 patients with the Kiistala method, every 1-2 weeks for at least 1 month.
RESULTS: During the observation period, all the patients showed disease improvement (median PASI score declined from 13.4 to 3.9) and significant decreases in the cytokine levels in all samples.
CONCLUSION: These results are in agreement with a functional involvement of these two cytokines in the pathogenesis of the disease and their possible use as follow-up markers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873820     DOI: 10.1159/000246879

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  Biologics in the management of psoriasis.

Authors:  Jennifer D Bahner; Lauren Y Cao; Neil J Korman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-07-23

2.  Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis.

Authors:  Anna Zalewska; Ewa Głowacka; Janina Wyczółkowska; Henryk Tchórzewski; Joanna Narbutt; Anna Sysa-Jedrzejowska
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

3.  Evidence for local inflammation in complex regional pain syndrome type 1.

Authors:  Frank J P M Huygen; Anke G J De Bruijn; Martha T De Bruin; J George Groeneweg; Jan Klein; Freek J Zijlstra
Journal:  Mediators Inflamm       Date:  2002-02       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.